Alle belangrijke punten van Relief (nog een keer) opgesomd.
The following is a summary for new investors, or those who need to be reminded of the potential here:
This is an edited version of what "Uncle Gee Gee" at another site:
• Aviptadil is a safe, synthetic version of a naturally occurring peptide in the human body, which increases surfactant production in the lungs. It has been proven to be safe since 1970’s.
• Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.
• Aviptadil has been approved safe in Europe for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction, and ARDS.
• An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. “Healthy volunteers have shown that inhaled aviptadil is well tolerated with few adverse effects.”
• Aviptadil is inexpensive and easy to manufacture.
• Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.
Stock/Company
• Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC).
• NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.
• NeuroRX’s CEO, Jonathan Javitt led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer, and was appointed to healthcare leadership roles under four different U.S. Presidents.
• Relief Therapeutics Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.
• Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.
Manufacturing, Distribution, and Expansion
• Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.
• Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.
• 2 Partnership arrangements are expected to be announced soon.
• “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt
• “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt
• “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt
• Dr. Gilles Corte was recently hired as the new CMO (Chief Medical Officer) to head up the clinical development of aviptadil in Europe, which confirms Relief’s commitment to additional international expansion.
• Relief up-listed from the OTC Pink exchange to the OTCQB exchange, and “intends to seek a future presence on a regulated exchange such as the NASDAQ or NYSE MKT”.
Clinical Trials
• Clinical Trial NCT04311697 – The initial clinical trial underway to test intravenously administered drug. Approximately 86 out of 122 patients had been recruited as of Aug 12, and the company’s data committee were to begin reviewing the cases once they reach 102 patients. Speculation: Review may have already happened, and submitted to FDA.
• Clinical Trial NCT04453839 – The FDA-approved Expanded Access program for treating patients who are too sick for clinical trials.
• Expanded Access results were released in a “pre-print” document, showing 19 of 21 patients have survived. These are the sickest of the sick (ICU, ventilators, ECMO patients). The pre-print is under peer review & expected to be officially released in the coming weeks. Contrast the survival of 19 out of 21 patients (90%) with, according to Dr Javitt, “published information on COVID says that 80% of patients on ECMO die and at least 30% if not 50% of patients on ventilators die.”
• Clinical Trial NCT04360096 – A study of 288 patients to test an inhaler-version of RLF-100, intended to ultimately be used for in-home treatments. Estimated completion of trial is November 30th. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
• Clinical trial #NCT04536350 was initiated for an inhaled version of aviptadil on Sept 2nd as a preventative treatment. The trial will take place in Switzerland.